Prognostic value of serum CA9 in patients with metastatic clear cell renal cell carcinoma under targeted therapy

Anticancer Research

Volumn 32, Issue 12, 2012, Pages 5447-5451

  Gigante, Marc ^a   Li, Guorong ^a   Ferlay, Celine ^b   Perol, David ^b   Blanc, Ellen ^b   Paul, Stephane ^a   Zhao, An ^a   Tostain, Jacques ^a   Escudier, Bernard ^c   Negrier, Sylvie ^b   Genin, Christian ^a  

^a UNIVERSITÉ JEAN MONNET   (France)

^b UNIVERSITÉ DE LYON   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Biomarker; Carbonic anhydrase 9; Metastatic RCC; Prognosis; Targeted therapy

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CARBONATE DEHYDRATASE IX; SUNITINIB; TEMSIROLIMUS;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INDOLES; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PYRROLES; SIROLIMUS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84872518357     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X and Figlin RA: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27(22): 3584-3590, 2009.
2. Stillebroer AB, Mulders PF, Boerman OC, Oyen WJ and Oosterwijk E: Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol 58(1): 75-83, 2010.
3. Tostain J, Li G, Gentil-Perret A and Gigante M: Carbonic anhydrase 9 in clear cell renal cell carcinoma: A marker for diagnosis, prognosis and treatment. Eur J Cancer 46(18): 3141-3148, 2010.
4. Robertson N, Potter C and Harris AL: Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res 64(17): 6160-6165, 2004.
5. Korkeila E, Talvinen K, Jaakkola PM, Minn H, Syrjanen K, Sundstrom J and Pyrhonen S: Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer. Br J Cancer 100(6): 874-880, 2009.
6. Klatte T, Seligson DB, Rao JY, Yu H, de Martino M, Kawaoka K, Wong SG, Belldegrun AS and Pantuck AJ: Carbonic anhydrase IX in bladder cancer: A diagnostic, prognostic, and therapeutic molecular marker. Cancer 115(7): 1448-1458, 2009.
7. Bui MH, Visapaa H, Seligson D, Kim H, Han KR, Huang Y, Horvath S, Stanbridge EJ, Palotie A, Figlin RA and Belldegrun AS: Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol 171(6 Pt 1): 2461-2466, 2004.
8. Li G, Feng G, Gentil-Perret A, Genin C and Tostain J: Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer. J Urol 180(2): 510-513, 2008. discussion 513-514.
9. Zavada J, Zavadova Z, Zat'ovicova M, Hyrsl L and Kawaciuk I: Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients. Br J Cancer 89(6): 1067-1071, 2003.
10. Zhou GX, Ireland J, Rayman P, Finke J and Zhou M: Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: Prognostic and diagnostic potentials. Urology 75(2): 257-261, 2010.
11. Ferrandina G, Ludovisi M, Corrado G, Carone V, Petrillo M and Scambia G: Prognostic role of CA125 response criteria and RECIST criteria: Analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol 109(2): 187-193, 2008.
12. Hussain M, Goldman B, Tangen C, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK, Burch PA, Dipaola RS and Crawford ED: Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol 27(15): 2450-2456, 2009.
13. Negrier S, Gravis G, Perol D, Chevreau C, Delva R, Bay JO, Blanc E, Ferlay C, Geoffrois L, Rolland F, Legouffe E, Sevin E, Laguerre B and Escudier B: Temsirolimus and bevacizumab, or sunitinib, or interferon-á and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): A randomised phase II trial. Lancet Oncol 12(7): 673-680, 2011.
14. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2): 228-247, 2009.
15. Farace F, Gross-Goupil M, Tournay E, Taylor M, Vimond N, Jacques N, Billiot F, Mauguen A, Hill C and Escudier B: Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors. Br J Cancer 104(7): 1144-1150, 2011.
16. Paule B, Bastien L, Deslandes E, Cussenot O, Podgorniak MP, Allory Y, Naimi B, Porcher R, de La Taille A, Menashi S, Calvo F and Mourah S: Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas. PLoS One 5(5): e10715, 2010.
17. Pena C, Lathia C, Shan M, Escudier B and Bukowski RM: Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res 16(19): 4853-4863, 2010.
18. Terakawa T, Miyake H, Kusuda Y and Fujisawa M: Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib. Urol Oncol in press.
19. Gruenwald V, Beutel G, Schuch-Jantsch S, Reuter C, Ivanyi P, Ganser A and Haubitz M: Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib. BMC Cancer 10: 695, 2010.
20. Escudier B: Progression-free survival as a surrogate marker of overall survival: Is it the good question? Cancer 117(12): 2586-2587, 2011.